Sodium butyrate ameliorates S100/FCA-induced autoimmune hepatitis through regulation of intestinal tight junction and toll-like receptor 4 signaling pathway

Autor: Xiao-Ya Jin, Lu Chen, Xiao-Dong Wang, Ming-Hua Zheng, En-De Hu, Jin-Lu Wu, Yong-Ping Chen, Yu Huang, Lanman Xu, Yuewen Gong, Da-Zhi Chen, Ming-Fang Zhao, Feng-Bin Lu, Hui Li, Jia-Yun Zou, Zhuo Lin

Publikováno v: Immunology Letters. 190:169-176

Background and aim Recent investigation revealed that dysbiosis in the gut flora and disruption of permeability of intestinal barrier are possible causes for the development of autoimmune hepatitis. Supplementation of sodium butyrate has been suggest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4822dff3933d51c4be66dd205c242fd
https://doi.org/10.1016/j.imlet.2017.08.005

The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis

Autor: Yong-Ping Chen, Lanman Xu, Jin-Lu Wu, Hui Li, Da-Zhi Chen, Lu Chen, Feng-Bin Lu, En-De Hu

Publikováno v: Expert review of gastroenterologyhepatology. 12(5)

A number of researches have explored the association between obesity and nonalcoholic fatty liver disease (NAFLD) liver function, histopathology, complications, genetic factors and prognosis, but the results were conflicting and inconclusive. Areas c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c1ec83b1f22193d36c98c0d344ecf66
https://pubmed.ncbi.nlm.nih.gov/29609501

High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier

Autor: Yu Huang, Lu Chen, Xiao-Ya Jin, Ming-Hua Zheng, Zhuo Lin, Ji Li, En-De Hu, Xiao-Dong Wang, Lanman Xu, Yong-Ping Chen, Jin-Lu Wu, Feng-Bin Lu, Hui Li, Yuewen Gong, Da-Zhi Chen

Publikováno v: Cellular immunology. 328

Autoimmune hepatitis (AIH) is chronic autoimmune liver disease accompanied with the imbalance of Treg/Th17 and increased intestinal permeability. We investigated the effects of a high fiber diet and sodium butyrate on the Treg/Th17 and intestinal bar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2e99c2e858635fe83e6616eb36984c
https://pubmed.ncbi.nlm.nih.gov/29627063

Probing hepatic metabolism of [2- ¹³ C]dihydroxyacetone in vivo with ¹ H-decoupled hyperpolarized ¹³ C-MR.

Autor: Marco-Rius I; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. imarco@ibecbarcelona.eu.; Institute for Bioengineering of Catalonia, Barcelona, Spain. imarco@ibecbarcelona.eu., Wright AJ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Hu DE; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Savic D; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.; Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Division of Medicine, University of Oxford, Oxford, UK., Miller JJ; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.; Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Division of Medicine, University of Oxford, Oxford, UK., Timm KN; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK., Tyler D; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.; Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Division of Medicine, University of Oxford, Oxford, UK., Brindle KM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Comment A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.; General Electric Healthcare, Chalfont St Giles, UK.

Publikováno v: Magma (New York, N.Y.) [MAGMA] 2021 Feb; Vol. 34 (1), pp. 49-56. Date of Electronic Publication: 2020 Sep 10.

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER ⁺ Breast Cancer.

Autor: Ros S; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK. Electronic address: susana.ros@cruk.cam.ac.uk., Wright AJ; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., D'Santos P; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Hu DE; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Hesketh RL; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Lubling Y; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Georgopoulou D; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Lerda G; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Couturier DL; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK., Razavi P; Human Oncology and Pathogenesis Program, X and Department of Pathology, Y and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pelossof R; Human Oncology and Pathogenesis Program, X and Department of Pathology, Y and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Batra AS; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Mannion E; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Lewis DY; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Martin A; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Baird RD; Breast Cancer Research Programme, Cancer Research UK Cambridge Centre, Cambridge, UK., Oliveira M; Medical Oncology, Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., de Boo LW; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Scaltriti M; Human Oncology and Pathogenesis Program, X and Department of Pathology, Y and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rueda OM; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Bruna A; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Caldas C; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK., Brindle KM; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cancer Research UK Cambridge Cancer Centre, Cambridge, UK; Department of Biochemistry, University of Cambridge, Cambridge UK. Electronic address: kmb1001@cam.ac.uk.

Publikováno v: Cancer cell [Cancer Cell] 2020 Oct 12; Vol. 38 (4), pp. 516-533.e9. Date of Electronic Publication: 2020 Sep 24.